Corpus ID: 16752462

KDR/VEGFR-2 Receptor Tyrosine Kinase Inhibitors and 3D QSAR (CoMFA and CoMSIA) Study

@article{Yasala2016KDRVEGFR2RT,
  title={KDR/VEGFR-2 Receptor Tyrosine Kinase Inhibitors and 3D QSAR (CoMFA and CoMSIA) Study},
  author={A. K. Yasala and T. Khan},
  journal={Research and reviews: journal of medical and health sciences},
  year={2016},
  volume={2016}
}
  • A. K. Yasala, T. Khan
  • Published 2016
  • Medicine
  • Research and reviews: journal of medical and health sciences
    • ABSTRACT The review illustrates on the Vascular endothelial growth factor-A (VEGF-A) which shows pivotal roles in many angiogenic processes both in stable and pathological condition. Angiogenesis plays a key role in a number of pathology conditions with VEGFR-2 signals implicated in both tumour angiogenesis and diabetic retinopathy. 
    rroij.com

    References

    SHOWING 1-10 OF 88 REFERENCES
    Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
    • 25
    Pharmacophore based 3D-QSAR study of VEGFR-2 inhibitors
    • 13
    Pharmacophore and docking-based combined in-silico study of KDR inhibitors.
    • 40
    Novel Drug Development of the Next-Generation T790M Mutant SpecificEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for theTreatment of Advanced Non-Small Cell Lung Cancer
    • 4
    Lymphangiogenesis in Cancer: A Review
    • 12
    Aurora Kinase Inhibitors in Target Specific Cancer Treatment
    • 1
    • PDF
    Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals
    • 4
    • PDF
    Reversible Hepatic Cytolysis Secondary to Sunitinib in Metastatic Renal Carcinoma
    • 7
    • PDF
    Cancer Treatment in the Checkpoint Inhibitor Era
    • 2
    Therapeutic Interventions Using Ursolic Acid for Cancer Treatment
    • 6
    • PDF